Takeda Pharmaceutical investors may have been skeptical of Takeda's $62 billion acquisition of Shire at first, but Bloomberg believes they'll eventually come around.
Here's what you should know.
1. Bloomberg is calling the Shire acquisition, "the best thing that could have happened to the Japanese drugmaker."
2. Shire allows Takeda a pathway into the U.S.
Bloomberg said the only other way Takeda could've got such exposure was if it acquired either Celgene Corp. or Biogen. Both companies would've set Takeda back a considerable amount more than the $62 billion Shire was acquired for.
3. Although Shire has the potential to strain Takeda's budget without realizing many short-term returns, Shire significantly boosts Takeda's presence in the rare disease drugs market which has a massive amount of cash flow.
4. The acquisition is not without its risks, but "maybe, in taking a risk, Takeda will cement its place in the global pharmaceuticals market. With its stock rallying as much as 3.7 percent [May 10], it seems some shareholders at least share the view that in Shire, Takeda has found the savior it sorely needed."